<DOC>
	<DOCNO>NCT01824017</DOCNO>
	<brief_summary>The current proposal extend work do mouse model evaluate consistency measure RLIP76 clinical cohort ( Aim 1 ) use guideline provide NIH validate biomarkers . We also proceed estimate effect size potential correlation RLIP76 standard MsY treatment measure hgbA1c , LDL , triglyceride level longitudinal prospective study ( Aim 2 ) follow cohort patient MsY seek care City Hope Endocrine clinic 12 month period..</brief_summary>
	<brief_title>Validation RLIP76 Assay Humans</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Registered patient City Hope follow Endocrine Clinic . Must documentation diagnosis diabetes identify problem list patient 's electronic health record . Must demonstrate feature MsY possess follow characteristic and/or receive treatment diabetes , hyperlipidemia , and/or hypertriglyceridemia . Central obesity : waist circumference ≥ 102 cm 40 inch ( male ) , ≥ 88 cm 36 inch ( female ) Dyslipidemia : TG ≥ 1.7 mmol/L ( 150 mg/dl ) Dyslipidemia : HDLC &lt; 40 mg/dL ( male ) , &lt; 50 mg/dL ( female ) Blood pressure ≥ 130/85 mmHg Fasting plasma glucose ≥ 6.1 mmol/L ( 110 mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>GSH</keyword>
</DOC>